Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Surrozen, Inc.NASDAQ: SRZN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.13M rose 54.1% year over year, ahead of the +21.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 46.7% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.
Context
- Selling, general & admin amounted to 466.0% of revenue in FY2025, up 324.7 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $19.71M (+21.6%) for the fiscal year ending Dec 2026, a step up from the +7.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.13M+46.7% QoQ
- Last fiscal yearDec 2025
- $16.2M+7.6% YoY
- LTMMar 2026
- $18.36M+21.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 16.2M USD
- Year-over-year change
- +7.6%
- 4-year CAGR
- +3.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.2M | +7.6% |
| FY2024 | 2024-12-31 | 15.06M | -4.7% |
| FY2023 | 2023-12-31 | 15.8M | -20.3% |
| FY2022 | 2022-12-31 | 19.83M | +39.5% |
| FY2021 | 2021-12-31 | 14.21M | — |
Selling, General & Admin vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's LTM Mar 2026 selling, general & admin of $18.36M is the 5th highest of the 8 companies compared; the peer median is $21.57M.
- Its year-over-year change of +21.1% is the 2nd highest of 8, against a peer median of -24.5%.
- Selling, general & admin amounts to 244.9% of revenue for SRZN, versus a peer median of 180.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $45.53M | -35.6% | -12.4% | 36.8% | |
| LTM Mar 2026 | $40.57M | -24.5% | -6.8% | 269.8% | |
| LTM Mar 2026 | $23.46M | -41.6% | -24.1% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $21.57M | +8.6% | +44.6% | 180.0% |
| LTM Mar 2026 | $18.36M | +21.1% | -6.5% | 244.9% | |
| LTM Mar 2026 | $15.81M | +34.6% | +50.4% | — | |
| LTM Mar 2026 | $10.32M | -12.0% | -7.1% | — | |
| LTM Mar 2026 | $2.36M | -26.5% | +12.5% | — | |
| Peer median (excluding SRZN) | $21.57M | -24.5% | -6.8% | 180.0% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.5M | 0 | 10.66M | 3.48M |
| Cost of Revenue | 3.3M | 3.27M | 27.23M | 0 | 537K |
| Gross Profit | (3.3M) | 9.23M | (27.23M) | 10.66M | 2.94M |
| Gross Margin | — | 73.8% | — | 100.0% | 84.6% |
| Research & Development | 36.88M | 37.01M | 27.23M | 21.13M | 29.37M |
| Selling, General & Admin | 14.21M | 19.83M | 15.8M | 15.06M | 16.2M |
| Operating Expenses | 51.09M | 53.57M | 18.55M | 36.19M | 45.03M |
| Depreciation & Amortization | 3.3M | 1.96M | 1.91M | 1.44M | 537K |
| EBITDA | (51.35M) | (34.05M) | (41.13M) | (62.12M) | (241.49M) |
| EBITDA Margin | — | -272.4% | — | -583.0% | -6945.3% |
| Operating Income | (54.39M) | (44.34M) | (45.78M) | (25.54M) | (42.09M) |
| Operating Margin | — | -354.7% | — | -239.7% | -1210.6% |
| Interest Income | 72K | 781K | 2.34M | 1.69M | 3.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (257K) | 8.34M | 2.74M | (38.03M) | (199.93M) |
| Income Before Tax | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Pre-Tax Margin | — | -288.0% | — | -596.6% | -6960.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.51M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Net Margin | — | -288.0% | — | -596.6% | -6960.8% |
| EPS (Basic) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| EPS (Diluted) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| Weighted Avg Shares | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
| Weighted Avg Shares (Diluted) | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.